NCT06041061View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

18,000

Participants

Timeline

Start Date

August 13, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

August 31, 2028

Conditions
HPV InfectioNHPV-Related Carcinoma
Interventions
BIOLOGICAL

Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）

According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine

BIOLOGICAL

placebo

According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo

Trial Locations (5)

Unknown

Guangxi Center for Disease Control and Prevention, Nanning

Henan Center for Disease Control and Prevention, Zhengzhou

Shanxi Center for Disease Control and Prevention, Taiyuan

Sichuan Center for Disease Control and Prevention, Chengdu

Yunan Center for Disease Control and Prevention, Kunming

All Listed Sponsors
collaborator

Guangxi Center for Disease Control and Prevention

OTHER_GOV

collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

collaborator

Sichuan Center for Disease Control and Prevention

OTHER_GOV

collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

collaborator

Yunnan Center for Disease Control and Prevention

OTHER

lead

Sinocelltech Ltd.

INDUSTRY